Emily Pimblett
Known title: CHIEF ACCOUNTING OFFICERCIK: 0001969365
Associated companies
Transaction History
| CLYM | ▼ Sell | Open Market | 1,242 | $2K | 6/20/2025 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 5,000 | — | 6/18/2025 | View on chart |
| CLYM | ▼ Sell | Open Market | 1,199 | $2K | 3/20/2025 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 5,000 | — | 3/18/2025 | View on chart |
| CLYM | ▼ Sell | Open Market | 1,235 | $2K | 12/19/2024 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 5,000 | — | 12/18/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 1,182 | $10K | 9/20/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 9 | $73 | 9/20/2024 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 5,000 | — | 9/18/2024 | View on chart |
| CLYM | ▼ Sell | Open Market | 1,245 | $9K | 6/20/2024 | View on chart |
| CLYM | ▲ Buy | Option Exercise | 5,000 | — | 6/18/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets
Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.
Climb Bio Shares Jump on Kidney Drug Dosing Data; Analysts Raise Targets. Climb Bio saw shares climb roughly 17% after its Phase 1 trial for the kidney disease drug CLYM116 produced data supporting a 12-week dosing schedule for IgA nephropathy patients. The positive results prompted several analysts to raise their price targets, with targets now ranging from $25 to $32 per share. The stock has gained an extraordinary 1,300% over the past 17 months but recently experienced a pullback from those levels, suggesting profit-taking activity following the surge.